Long‐Term Disease Control Following Completion of Cladribine Treatment in Multiple Sclerosis: Extended Follow‐Up of the CladStop Cohort
European Journal of Neurology · 2026-11 · 33 (11)
DOI: 10.1111/ene.70763 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 30.10.2026. Verfasst von Irene Schiavetti und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University of Genoa, Genova, Italy. Hauptthemen laut MEDLINE: Cladribine, Immunosuppressive Agents, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Long‐term disease control after the standard two‐year cladribine course in multiple sclerosis (MS) remains insufficiently characterized in real‐world settings. We evaluated disease control, treatment re‐initiation, and safety during extended follow‐up of the multicenter CladStop cohort after treatment completion.
Methods
We included 204 patients with relapsing MS who completed the approved two‐year cladribine regimen and had ≥ 6 months of follow‐up after treatment completion. Time zero (“CladStop”) was defined as 24 months after first cladribine dosing. Co‐primary endpoints were time to loss of no evidence of disease activity (NEDA‐3) and annualized relapse rate (ARR) after CladStop. Kaplan–Meier analyses, multivariable Cox models, and mixed‐effects Poisson regression were applied.
Results
Mean follow‐up after CladStop was 44.2 ± 8.6 months. Overall, 81/204 patients (39.7%) lost NEDA‐3. NEDA‐3 survival was 82.8% (95% CI 77.8–88.2) at 12 months, 69.6% (95% CI 63.6–76.2) at 24 months, and 56.4% (95% CI 49.2–64.8) at 48 months. Forty‐two patients (20.6%) relapsed, with an overall ARR of 0.06 (95% CI 0.04–0.08). Relapse rates decreased over time (rate ratio/year 0.74, 95% CI 0.55–0.999; p = 0.044). MRI activity occurred in 29.9% of patients and 6‐month confirmed disability progression in 7.4%. A new DMT was initiated in 40.7% of patients. Relapses during treatment predicted earlier DMT initiation.
Conclusions
Disease control remained durable in many patients after completion of cladribine treatment. However, over 40% initiated subsequent DMT during follow‐up, indicating that prolonged treatment‐free remission is not universal. Disease reactivation was driven mainly by inflammatory activity rather than disability worsening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, University of Genoa, Genova, Italy.
- IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy.
- Centro Sclerosi Multipla Ospedale Binaghi Cagliari, Azienda Sanitaria Locale (ASL) Cagliari, Cagliari, Italy.
- Dipartimento Scienze Mediche e Sanità Pubblica, Università di Cagliari, Cagliari, Italy.
- Unit of Neurology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, Pozzilli, Italy.
- Department of Systems Medicine, Tor Vergata University, Rome, Italy.
ORCID-Profile: Irene Schiavetti, Alessio Signori, Jessica Frau, Eleonora Cocco, Lorena Lorefice, Roberta Fantozzi, Diego Centonze, Doriana Landi, Girolama Marfia, Elisabetta Signoriello, Chiara Zecca, Claudio Gobbi, Rosa Iodice, Leonardo Malimpensa, Diana Ferraro, Livia Pasquali, Paolo Immovilli, Simona Bonavita, Massimiliano Di Filippo, Gianmarco Abbadessa, Maria Pia Sormani
Zitieren
APA
Schiavetti, I., Signori, A., Albanese, A., Frau, J., Cocco, E., Lorefice, L., di Lemme, S., Fantozzi, R., Centonze, D., Landi, D., Marfia, G., Signoriello, E., Lus, G., Zecca, C., Gobbi, C., Iodice, R., Malimpensa, L., Cordioli, C., Ferraro, D., …, & CladStop Study Group (2026). Long‐Term Disease Control Following Completion of Cladribine Treatment in Multiple Sclerosis: Extended Follow‐Up of the CladStop Cohort. European Journal of Neurology, 33(11). https://doi.org/10.1111/ene.70763
Vancouver
Schiavetti I, Signori A, Albanese A, Frau J, Cocco E, Lorefice L, et al. Long‐Term Disease Control Following Completion of Cladribine Treatment in Multiple Sclerosis: Extended Follow‐Up of the CladStop Cohort. European Journal of Neurology. 2026;33(11). doi:10.1111/ene.70763
BibTeX
@article{Schiavetti2026,
author = {Schiavetti, Irene and Signori, Alessio and Albanese, Angela and Frau, Jessica and Cocco, Eleonora and Lorefice, Lorena and di Lemme, Sonia and Fantozzi, Roberta and Centonze, Diego and Landi, Doriana and Marfia, Girolama and Signoriello, Elisabetta and Lus, Giacomo and Zecca, Chiara and Gobbi, Claudio and Iodice, Rosa and Malimpensa, Leonardo and Cordioli, Cinzia and Ferraro, Diana and Ruscica, Francesca and Pasquali, Livia and Repice, Anna and Immovilli, Paolo and Ferrò, Maria Teresa and Bonavita, Simona and Di Filippo, Massimiliano and Abbadessa, Gianmarco and Govone, Flora and Sormani, Maria Pia and CladStop Study Group, CladStop Study Group},
title = {Long‐Term Disease Control Following Completion of Cladribine Treatment in Multiple Sclerosis: Extended Follow‐Up of the CladStop Cohort},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {11},
doi = {10.1111/ene.70763}
}
EUVIMED